Equities Analysts Offer Predictions for RYTM Q1 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Investment analysts at HC Wainwright lowered their Q1 2025 earnings estimates for Rhythm Pharmaceuticals in a research note issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.74) for the quarter, down from their prior estimate of ($0.68). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q2 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.87) EPS and Q1 2026 earnings at ($0.60) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The business had revenue of $41.83 million for the quarter, compared to analysts’ expectations of $38.48 million.

Other equities analysts also recently issued research reports about the company. Canaccord Genuity Group raised their price target on Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. JMP Securities reissued a “market outperform” rating and issued a $75.00 target price on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. Morgan Stanley restated an “overweight” rating and issued a $72.00 target price on shares of Rhythm Pharmaceuticals in a report on Friday, March 7th. Needham & Company LLC lifted their price target on shares of Rhythm Pharmaceuticals from $64.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, March 18th. Finally, The Goldman Sachs Group upped their price objective on shares of Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $69.46.

Rhythm Pharmaceuticals Price Performance

Shares of RYTM opened at $54.30 on Wednesday. Rhythm Pharmaceuticals has a 1-year low of $35.17 and a 1-year high of $68.58. The stock has a market cap of $3.43 billion, a price-to-earnings ratio of -12.54 and a beta of 2.30. The firm has a 50 day simple moving average of $55.26 and a 200-day simple moving average of $55.02.

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, CFO Hunter C. Smith sold 2,215 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total value of $126,742.30. Following the transaction, the chief financial officer now owns 109,929 shares in the company, valued at approximately $6,290,137.38. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Yann Mazabraud sold 75,000 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the transaction, the executive vice president now directly owns 40,370 shares in the company, valued at approximately $2,078,247.60. This trade represents a 65.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 108,131 shares of company stock valued at $5,781,098. Company insiders own 5.60% of the company’s stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Rhythm Pharmaceuticals during the fourth quarter worth about $4,259,000. GF Fund Management CO. LTD. purchased a new stake in shares of Rhythm Pharmaceuticals during the 4th quarter valued at about $72,000. Voloridge Investment Management LLC lifted its position in Rhythm Pharmaceuticals by 7.7% during the 4th quarter. Voloridge Investment Management LLC now owns 380,537 shares of the company’s stock worth $21,302,000 after acquiring an additional 27,214 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in Rhythm Pharmaceuticals by 2.3% in the 4th quarter. Two Sigma Advisers LP now owns 13,100 shares of the company’s stock worth $733,000 after acquiring an additional 300 shares during the period. Finally, State of Wyoming acquired a new stake in Rhythm Pharmaceuticals in the fourth quarter valued at approximately $61,000.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.